Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift?
In this real-world study, early third-line CNB exhibits potentially favorable effectiveness compared with other commonly used third-line ASMs, and tolerability remained acceptable. These findings support the need for larger prospective studies to better define optimal treatment sequencing in focal-onset DRE.
Authors
- Bruna Nucera (ORCID: https://orcid.org/0000-0002-6023-5616)
- Stefano Luca Sensi (ORCID: https://orcid.org/0000-0002-0710-2574)
- Giovanni Falcicchio (ORCID: https://orcid.org/0000-0003-0745-5246)
- Giacomo Evangelista (ORCID: https://orcid.org/0000-0002-1828-5345)
- Rita Agosto
- Mirella Russo
- Fedele Dono
Institutions
- Paracelsus Medical University (AT)
- University of Chieti-Pescara (IT)
- Krankenhaus Meran (IT)
- University of Bari Aldo Moro (IT)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1007/s40120-026-00911-5
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00